BioMedNewsBreaks Archive - Page 75 of 255

FridayJun 14, 2024 1:20 pm

BioMedNewsBreaks — Astrotech Corp. (NASDAQ: ASTC) Subsidiary Partners with Multistate Testing Lab to Market Proprietary AgLAB Solutions

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its subsidiary, AgLAB, have entered into a master lease agreement with SC Labs; the companies are working together to jointly market the AgLAB 1000-D2(TM) mass spectrometer and the AgLAB Maximum Value Process testing method to SC Labs customers. AgLAB has pioneered applications featuring the Astrotech Mass Spectrometer Technology that specifically target the hemp and cannabis markets while SC Labs, one of the largest multistate cannabis and hemp-testing labs in the United States, delivers industry-leading, science-based innovations in cannabis and hemp testing. The partnership between the two entities extends SC Labs’ analytical services directly…

ThursdayJun 13, 2024 2:05 pm

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives LOI with European Investment Bank for Loan-to-Equity Conversion

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has received a nonbinding letter of intent (“LOI”) from the European Investment Bank (“EIB”). According to the announcement, the LOI contains terms for converting EIB's loan of approximately $27.6 million into equity in the form of prefunded warrants; the warrants, which will be exercisable into American Depositary Shares (“ADSs”), represent 19.5% of the fully diluted capital of the company as well as capped variable return mostly in the form of…

ThursdayJun 13, 2024 1:29 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Marks Major Milestone in Preparations for NDA Submission, Global Suramin Supply

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently completed its three registration/validation batches of PAX-101, an IV formulation of suramin. “This accomplishment marks a significant step toward submitting a New Drug Application (‘NDA’) to the U.S. Food and Drug Administration (‘FDA’) in the fourth quarter of 2024. This step paves the way for potential commercial availability in the U.S. of suramin, the sole form for treating stage 1 Human African Trypanosomiasis (‘HAT’) caused by Trypanosoma brucei rhodesiense. This disease, fatal and neglected, represents a critical healthcare challenge,” a recent article reads. “This completion of…

WednesdayJun 12, 2024 1:52 pm

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Unveils New Online Medical Record Request Form, Is Featured in Latest Episode of Bell2Bell Podcast

HealthLynked (OTCQB: HLYK), a leading provider of healthcare technology solutions, has unveiled a new online medical record request form, which is integrated with DocuSign. According to the announcement, patients can now seamlessly request their medical records with only a few clicks, and the records are automatically added to the patients' HealthLynked Network profile. The integration with DocuSign, a pioneer in electronic-signature technology, makes the request process quick and easy. The new online request form allows patients to request records from multiple healthcare providers and laboratories while providing enhanced security; all records are easily accessed and managed within the user's HealthLynked…

TuesdayJun 11, 2024 2:32 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

Clene (NASDAQ: CLNN) is scheduled to present at the 72nd Emerging Growth Conference, hosted by leading independent small cap media portal EmergingGrowth.com. Taking place on June 12 - 13, 2024, the event identifies companies in a wide range of growth sectors with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth. Clene’s President and CEO Rob Etherington and CFO Morgan Brown will provide a keynote speech at the conference starting at 2:20 p.m. ET on June 12. To view the full press release, visit https://ibn.fm/a13Kr About Clene Inc. Clene (along with its…

TuesdayJun 11, 2024 1:37 pm

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug-platform company developing novel therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting the results of its recent phase 2/3 Alzheimer’s study. The study was designed to evaluate Buntanetap, the company’s lead drug candidate. According to the report, key findings indicate that Buntanetap showed statistically significant efficacy and safety in the treatment of both carriers and noncarriers of Apolipoprotein E4 (APOE4), a genetic cause of AD. The company has scheduled an investor call for today at 4:30 p.m. ET to provide more detailed information and outline future development plans…

TuesdayJun 11, 2024 1:15 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation at Upcoming Emerging Growth Conference

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, will be featured in this week’s Emerging Growth Conference. The conference is slated for June 12–13, 2024. According to the announcement, InMed Pharmaceuticals CEO Eric A. Adams will be presenting at the two-day event. During his presentation, Adams will provide a corporate overview of the company; the presentation will also include a Q&A session. Adams’ presentation is scheduled to begin at 1:45 p.m. EDT on June 13. An archived replay of the presentation will be available on the InMed Pharmaceuticals website.…

FridayJun 07, 2024 1:49 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company announced today that on June 5, 2024, it received a formal notification from the Listing Qualification Department of the Nasdaq Stock Market that it has regained compliance with the minimum $1.00 bid price requirement outlined in Nasdaq Listing Rule 5550(a)(2). The notification further stated that Scinai remains non-compliant with the equity requirement in Listing Rule 5550(b)(1) or any of the alternative requirements under Listing Rule 5550(b). Accordingly, on June 18, 2024,…

WednesdayJun 05, 2024 3:58 pm

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Secures ~$2.2M in Private Placement

Bluejay (NASDAQ: BJDX) is a medical diagnostics company that offers the Symphony technology platform, Symphony Cartridge and tests and testing devices for the diagnosis of allergic conjunctivitis and monitoring of disease progression in critical care settings. Aegis Capital Corp. announced that it acted as exclusive placement agent on a ~$2.2 million private placement for Bluejay Diagnostics. To view the Form 8-K filing, visit https://ibn.fm/3xAyc About Bluejay Diagnostics Inc. Bluejay operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force;…

WednesdayJun 05, 2024 3:49 pm

BioMedNewsBreaks — Astiva Health Inc. to Host Summer Gala

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, today announced the Astiva Health Summer Gala, to be held at its headquarters in Orange, California. The event marks a significant milestone for the company and is slated to take place from 5 p.m. to 10 p.m. PT on June 29, 2024. The gala will feature live music, a dynamic atmosphere, as well as an important announcement concerning the company’s future plans. A keynote address by Astiva Health’s executive team will highlight strategic initiatives as the company continues its journey towards excellence…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Astrotech Corp. (NASDAQ: ASTC) Subsidiary Partners with Multistate Testing Lab to Market Proprietary AgLAB Solutions

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives LOI with European Investment Bank for Loan-to-Equity Conversion

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Marks Major Milestone in Preparations for NDA Submission, Global Suramin Supply

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Unveils New Online Medical Record Request Form, Is Featured in Latest Episode of Bell2Bell Podcast

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation at Upcoming Emerging Growth Conference

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Secures ~$2.2M in Private Placement

BioMedNewsBreaks — Astiva Health Inc. to Host Summer Gala

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search